Aclaris Therapeutics, Inc. (ACRS)
Develops experimental medicines to treat immune system diseases like eczema and asthma.
$5.33-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+248.4%
The outlook
Aclaris is trading near the upper end of its 52-week range and above both its 50- and 200-day moving averages, signaling upward momentum. Analysts are overwhelmingly bullish with a Strong Buy consensus, and their average price target sits roughly 88% above the current price. The stock's technical positioning and analyst sentiment are notably aligned on the optimistic side.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 10 analysts
Price trendAbove its 50- & 200-day averages
52-week range88% of the way from its 52-week low to high
Price targetAvg target +88% vs current price
Analyst price target
~12-month · 10 analysts$10.00average target+87.6% vs now
Now $5.33
Low $4.00High $16.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$744.4M
52-wk high
$5.88
52-wk low
$1.46
50-day avg
$4.91
200-day avg
$3.67
Trailing P/E
—